Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary
Identifieur interne : 000D67 ( Istex/Corpus ); précédent : 000D66; suivant : 000D68Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary
Auteurs : Peter A. GrossSource :
- Journal of Infectious Diseases [ 0022-1899 ] ; 1977.
Abstract
The reactivity and immunogenicity of bivalent (A/New Jersey/76 and A/Victoria/ 75) influenza vaccines in children are summarized for all high-risk and normal groups. Two whole-virus vaccines (WVVs) manufactured by Merck Sharp and Dohme (MSD; West Point, Pennsylvania) and Merrell-National Laboratories, (MN; Cincinnati, Ohio) and one split-product vaccine (SPV) produced by Parke, Davis and Company (PD; Detroit, Michigan) were compared. The first study was a onedose trial in the six- to 18-year-old group. The reaction index and percentage of children with temperatures of ⩾102 F were negligible in the groups given placebo and SPV but were significantly higher in children receiving WVVs. The geometric mean titer of hemagglutination-inhibiting antibody and the percentage of children with titers of hemagglutination-inhibiting antibody of ⩾40 were greatest for WVVs, but no vaccine was sufficiently immunogenic. Therefore, a two-dose trial was conducted with PD 400/400 (the numbers refer to the number of chick cell-agglutinating units of each vaccine), MN 100/100, and MSD 50/50 for children aged six to 18 years and half these vaccine dosages for children aged three to five years The reactivity after administration of both WVVs was markedly reduced compared with that in the one-dose trial, and reactivity was not increased for the PD vaccine. Reactivity after the second dose of each vaccine was similar to that with placebo. After the second dose of WVV, 67%–75% of children had hemagglutination-inhibition titers of ⩾40; after the SPV this figure was 88%–90%. The serologic response to the A/Victoria/75 antigen was better than the response to the A/New Jersey antigen after one dose of vaccine. Thus, two doses of PD vaccine resulted in the greatest hemagglutination-inhibiting antibody response and the least reactivity in the subjects aged three to 18 years.
Url:
DOI: 10.1093/infdis/136.Supplement_3.S616
Links to Exploration step
ISTEX:2F3479F240463BF422D7A2DA798B5E1D47BD5B16Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary</title><author wicri:is="90%"><name sortKey="Gross, Peter A" sort="Gross, Peter A" uniqKey="Gross P" first="Peter A." last="Gross">Peter A. Gross</name><affiliation><mods:affiliation>Departments of Medicine of the College of Physicians and Surgeons, Columbia University, New York, New York, Hackensack, New Jersey</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2F3479F240463BF422D7A2DA798B5E1D47BD5B16</idno><date when="1977" year="1977">1977</date><idno type="doi">10.1093/infdis/136.Supplement_3.S616</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-WV6F7NPT-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000D67</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary</title><author wicri:is="90%"><name sortKey="Gross, Peter A" sort="Gross, Peter A" uniqKey="Gross P" first="Peter A." last="Gross">Peter A. Gross</name><affiliation><mods:affiliation>Departments of Medicine of the College of Physicians and Surgeons, Columbia University, New York, New York, Hackensack, New Jersey</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1977-12">1977</date><biblScope unit="vol">136</biblScope><biblScope unit="issue">Supplemet_3</biblScope><biblScope unit="page" from="S616">S616</biblScope><biblScope unit="page" to="S625">S625</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">The reactivity and immunogenicity of bivalent (A/New Jersey/76 and A/Victoria/ 75) influenza vaccines in children are summarized for all high-risk and normal groups. Two whole-virus vaccines (WVVs) manufactured by Merck Sharp and Dohme (MSD; West Point, Pennsylvania) and Merrell-National Laboratories, (MN; Cincinnati, Ohio) and one split-product vaccine (SPV) produced by Parke, Davis and Company (PD; Detroit, Michigan) were compared. The first study was a onedose trial in the six- to 18-year-old group. The reaction index and percentage of children with temperatures of ⩾102 F were negligible in the groups given placebo and SPV but were significantly higher in children receiving WVVs. The geometric mean titer of hemagglutination-inhibiting antibody and the percentage of children with titers of hemagglutination-inhibiting antibody of ⩾40 were greatest for WVVs, but no vaccine was sufficiently immunogenic. Therefore, a two-dose trial was conducted with PD 400/400 (the numbers refer to the number of chick cell-agglutinating units of each vaccine), MN 100/100, and MSD 50/50 for children aged six to 18 years and half these vaccine dosages for children aged three to five years The reactivity after administration of both WVVs was markedly reduced compared with that in the one-dose trial, and reactivity was not increased for the PD vaccine. Reactivity after the second dose of each vaccine was similar to that with placebo. After the second dose of WVV, 67%–75% of children had hemagglutination-inhibition titers of ⩾40; after the SPV this figure was 88%–90%. The serologic response to the A/Victoria/75 antigen was better than the response to the A/New Jersey antigen after one dose of vaccine. Thus, two doses of PD vaccine resulted in the greatest hemagglutination-inhibiting antibody response and the least reactivity in the subjects aged three to 18 years.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Peter A. Gross</name><affiliations><json:string>Departments of Medicine of the College of Physicians and Surgeons, Columbia University, New York, New York, Hackensack, New Jersey</json:string></affiliations></json:item></author><arkIstex>ark:/67375/HXZ-WV6F7NPT-C</arkIstex><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>The reactivity and immunogenicity of bivalent (A/New Jersey/76 and A/Victoria/ 75) influenza vaccines in children are summarized for all high-risk and normal groups. Two whole-virus vaccines (WVVs) manufactured by Merck Sharp and Dohme (MSD; West Point, Pennsylvania) and Merrell-National Laboratories, (MN; Cincinnati, Ohio) and one split-product vaccine (SPV) produced by Parke, Davis and Company (PD; Detroit, Michigan) were compared. The first study was a onedose trial in the six- to 18-year-old group. The reaction index and percentage of children with temperatures of ⩾102 F were negligible in the groups given placebo and SPV but were significantly higher in children receiving WVVs. The geometric mean titer of hemagglutination-inhibiting antibody and the percentage of children with titers of hemagglutination-inhibiting antibody of ⩾40 were greatest for WVVs, but no vaccine was sufficiently immunogenic. Therefore, a two-dose trial was conducted with PD 400/400 (the numbers refer to the number of chick cell-agglutinating units of each vaccine), MN 100/100, and MSD 50/50 for children aged six to 18 years and half these vaccine dosages for children aged three to five years The reactivity after administration of both WVVs was markedly reduced compared with that in the one-dose trial, and reactivity was not increased for the PD vaccine. Reactivity after the second dose of each vaccine was similar to that with placebo. After the second dose of WVV, 67%–75% of children had hemagglutination-inhibition titers of ⩾40; after the SPV this figure was 88%–90%. The serologic response to the A/Victoria/75 antigen was better than the response to the A/New Jersey antigen after one dose of vaccine. Thus, two doses of PD vaccine resulted in the greatest hemagglutination-inhibiting antibody response and the least reactivity in the subjects aged three to 18 years.</abstract><qualityIndicators><score>8.667</score><pdfWordCount>5031</pdfWordCount><pdfCharCount>30180</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>612 x 768.96 pts</pdfPageSize><pdfWordsPerPage>503</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>false</refBibsNative><abstractWordCount>284</abstractWordCount><abstractCharCount>1873</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary</title><pmid><json:string>606783</json:string></pmid><genre><json:string>research-article</json:string></genre><host><title>Journal of Infectious Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0022-1899</json:string></issn><eissn><json:string>1537-6613</json:string></eissn><publisherId><json:string>jid</json:string></publisherId><volume>136</volume><issue>Supplement-3</issue><pages><first>S616</first><last>S625</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1977</json:string></date><geogName></geogName><orgName><json:string>Clinical Research Committee of the National Institute of Allergy and Infectious Diseases</json:string><json:string>Merrell-National Laboratories</json:string><json:string>Columbia University</json:string><json:string>Wyeth Laboratories</json:string><json:string>University of Rochester</json:string><json:string>MerrellNational Laboratories</json:string><json:string>University of California, Los Angeles</json:string><json:string>Vanderbilt University</json:string><json:string>NIAID</json:string><json:string>University of Nebraska</json:string><json:string>University of Colorado</json:string><json:string>Hackensack Hospital, Hackensack, New Jersey The</json:string><json:string>University of Maryland</json:string><json:string>University of Texas, San Antonio</json:string><json:string>Duke University</json:string><json:string>Hackensack Hospital, Hackensack</json:string><json:string>Merrill-National Laboratories</json:string><json:string>Children's Hospital, Washington</json:string><json:string>Children's Hospital Medical Center, Boston, Mass</json:string><json:string>University of Washington</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Kenneth McIntosh</json:string><json:string>Steven Lerman</json:string><json:string>Peter A. Gross</json:string><json:string>M. Levine</json:string><json:string>James D. Cherry</json:string><json:string>S. Reactivity</json:string><json:string>Caroline B. Hall</json:string><json:string>John Modlin</json:string><json:string>M. Foy</json:string><json:string>V. Sumaya</json:string><json:string>Bettina Hilman</json:string><json:string>Peter Wright</json:string><json:string>Samuel Katz</json:string><json:string>Rls</json:string></persName><placeName><json:string>Durham</json:string><json:string>Rochester</json:string><json:string>Nashville</json:string><json:string>Immunogenicity</json:string><json:string>Cincinnati</json:string><json:string>Seattle</json:string><json:string>Atlanta</json:string><json:string>Baltimore</json:string><json:string>N.Y.</json:string><json:string>N.C.</json:string><json:string>York</json:string><json:string>Detroit</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[4]</json:string><json:string>[12]</json:string><json:string>[10, 11]</json:string><json:string>Ennis et al. [5]</json:string><json:string>[8]</json:string><json:string>[1]</json:string><json:string>Barry et al. [6]</json:string><json:string>[2, 3]</json:string><json:string>[7]</json:string><json:string>[9]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/HXZ-WV6F7NPT-C</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - microbiology</json:string><json:string>2 - infectious diseases</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - microbiology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1977</publicationDate><copyrightDate>1977</copyrightDate><doi><json:string>10.1093/infdis/136.Supplement_3.S616</json:string></doi><id>2F3479F240463BF422D7A2DA798B5E1D47BD5B16</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-WV6F7NPT-C/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-WV6F7NPT-C/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-WV6F7NPT-C/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>The University of Chicago Press</publisher><availability><licence>© 1977 the University of Chicago</licence></availability><date type="Copyright" when="1977">1977</date><date when="1977-12">1977</date></publicationStmt><notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary</title><author xml:id="author-0000" role="corresp"><persName><surname>Gross</surname><forename type="first">Peter A.</forename></persName><affiliation><orgName type="institution">Departments of Medicine of the College of Physicians and Surgeons</orgName><orgName type="institution">Columbia University</orgName><address><addrLine>New York, New York</addrLine></address></affiliation><affiliation><orgName type="institution">Hackensack Hospital</orgName><address><addrLine>Hackensack, New Jersey</addrLine></address></affiliation><affiliation role="corresp"><address><addrLine>Room 118, Hackensack Hospital, Hackensack, NewJersey 07601</addrLine></address></affiliation></author><idno type="istex">2F3479F240463BF422D7A2DA798B5E1D47BD5B16</idno><idno type="ark">ark:/67375/HXZ-WV6F7NPT-C</idno><idno type="DOI">10.1093/infdis/136.Supplement_3.S616</idno></analytic><monogr><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="hwp">jinfdis</idno><idno type="publisher-id">jid</idno><idno type="pISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1977-12">1977</date><biblScope unit="vol">136</biblScope><biblScope unit="issue">Supplemet_3</biblScope><biblScope unit="page" from="S616">S616</biblScope><biblScope unit="page" to="S625">S625</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract><p>The reactivity and immunogenicity of bivalent (A/New Jersey/76 and A/Victoria/ 75) influenza vaccines in children are summarized for all high-risk and normal groups. Two whole-virus vaccines (WVVs) manufactured by Merck Sharp and Dohme (MSD; West Point, Pennsylvania) and Merrell-National Laboratories, (MN; Cincinnati, Ohio) and one split-product vaccine (SPV) produced by Parke, Davis and Company (PD; Detroit, Michigan) were compared. The first study was a onedose trial in the six- to 18-year-old group. The reaction index and percentage of children with temperatures of ⩾102 F were negligible in the groups given placebo and SPV but were significantly higher in children receiving WVVs. The geometric mean titer of hemagglutination-inhibiting antibody and the percentage of children with titers of hemagglutination-inhibiting antibody of ⩾40 were greatest for WVVs, but no vaccine was sufficiently immunogenic. Therefore, a two-dose trial was conducted with PD 400/400 (the numbers refer to the number of chick cell-agglutinating units of each vaccine), MN 100/100, and MSD 50/50 for children aged six to 18 years and half these vaccine dosages for children aged three to five years The reactivity after administration of both WVVs was markedly reduced compared with that in the one-dose trial, and reactivity was not increased for the PD vaccine. Reactivity after the second dose of each vaccine was similar to that with placebo. After the second dose of WVV, 67%–75% of children had hemagglutination-inhibition titers of ⩾40; after the SPV this figure was 88%–90%. The serologic response to the A/Victoria/75 antigen was better than the response to the A/New Jersey antigen after one dose of vaccine. Thus, two doses of PD vaccine resulted in the greatest hemagglutination-inhibiting antibody response and the least reactivity in the subjects aged three to 18 years.</p></abstract><textClass ana="subject"><keywords scheme="heading"><term>Session III. Vaccine Trials</term></keywords><keywords scheme="heading"><term>E. Bivalent Vaccine in Children: One- and Two-Dose Trials</term></keywords></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2019-12-13">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-WV6F7NPT-C/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="hwp">jinfdis</journal-id>
<journal-id journal-id-type="publisher-id">jid</journal-id>
<journal-title>Journal of Infectious Diseases</journal-title>
<abbrev-journal-title>J Infect Dis.</abbrev-journal-title>
<issn pub-type="ppub">0022-1899</issn>
<issn pub-type="epub">1537-6613</issn>
<publisher>
<publisher-name>The University of Chicago Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1093/infdis/136.Supplement_3.S616</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Session III. Vaccine Trials</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>E. Bivalent Vaccine in Children: One- and Two-Dose Trials</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Gross</surname><given-names>Peter A.</given-names></name><xref ref-type="corresp" rid="cor1"></xref>
</contrib>
<aff><institution>Departments of Medicine of the College of Physicians and Surgeons, Columbia University</institution>, <addr-line>New York, New York</addr-line></aff>
<aff><institution>Hackensack Hospital</institution>, <addr-line>Hackensack, New Jersey</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Please address requests for reprints to Dr. Peter A. Gross, <institution>Johnson Hall</institution>, <addr-line>Room 118, Hackensack Hospital, Hackensack, NewJersey 07601</addr-line>.</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>12</month>
<year>1977</year>
</pub-date>
<volume>136</volume>
<issue>Supplement_3</issue>
<fpage>S616</fpage>
<lpage>S625</lpage>
<copyright-statement>© 1977 the University of Chicago</copyright-statement>
<copyright-year>1977</copyright-year>
<abstract>
<p>The reactivity and immunogenicity of bivalent (A/New Jersey/76 and A/Victoria/ 75) influenza vaccines in children are summarized for all high-risk and normal groups. Two whole-virus vaccines (WVVs) manufactured by Merck Sharp and Dohme (MSD; West Point, Pennsylvania) and Merrell-National Laboratories, (MN; Cincinnati, Ohio) and one split-product vaccine (SPV) produced by Parke, Davis and Company (PD; Detroit, Michigan) were compared. The first study was a onedose trial in the six- to 18-year-old group. The reaction index and percentage of children with temperatures of ⩾102 F were negligible in the groups given placebo and SPV but were significantly higher in children receiving WVVs. The geometric mean titer of hemagglutination-inhibiting antibody and the percentage of children with titers of hemagglutination-inhibiting antibody of ⩾40 were greatest for WVVs, but no vaccine was sufficiently immunogenic. Therefore, a two-dose trial was conducted with PD 400/400 (the numbers refer to the number of chick cell-agglutinating units of each vaccine), MN 100/100, and MSD 50/50 for children aged six to 18 years and half these vaccine dosages for children aged three to five years The reactivity after administration of both WVVs was markedly reduced compared with that in the one-dose trial, and reactivity was not increased for the PD vaccine. Reactivity after the second dose of each vaccine was similar to that with placebo. After the second dose of WVV, 67%–75% of children had hemagglutination-inhibition titers of ⩾40; after the SPV this figure was 88%–90%. The serologic response to the A/Victoria/75 antigen was better than the response to the A/New Jersey antigen after one dose of vaccine. Thus, two doses of PD vaccine resulted in the greatest hemagglutination-inhibiting antibody response and the least reactivity in the subjects aged three to 18 years.</p>
</abstract>
</article-meta>
</front>
</article>
</istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary</title></titleInfo><name type="personal"><namePart type="given">Peter A.</namePart><namePart type="family">Gross</namePart><affiliation>Departments of Medicine of the College of Physicians and Surgeons, Columbia University, New York, New York, Hackensack, New Jersey</affiliation></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">1977-12</dateIssued><copyrightDate encoding="w3cdtf">1977</copyrightDate></originInfo><abstract>The reactivity and immunogenicity of bivalent (A/New Jersey/76 and A/Victoria/ 75) influenza vaccines in children are summarized for all high-risk and normal groups. Two whole-virus vaccines (WVVs) manufactured by Merck Sharp and Dohme (MSD; West Point, Pennsylvania) and Merrell-National Laboratories, (MN; Cincinnati, Ohio) and one split-product vaccine (SPV) produced by Parke, Davis and Company (PD; Detroit, Michigan) were compared. The first study was a onedose trial in the six- to 18-year-old group. The reaction index and percentage of children with temperatures of ⩾102 F were negligible in the groups given placebo and SPV but were significantly higher in children receiving WVVs. The geometric mean titer of hemagglutination-inhibiting antibody and the percentage of children with titers of hemagglutination-inhibiting antibody of ⩾40 were greatest for WVVs, but no vaccine was sufficiently immunogenic. Therefore, a two-dose trial was conducted with PD 400/400 (the numbers refer to the number of chick cell-agglutinating units of each vaccine), MN 100/100, and MSD 50/50 for children aged six to 18 years and half these vaccine dosages for children aged three to five years The reactivity after administration of both WVVs was markedly reduced compared with that in the one-dose trial, and reactivity was not increased for the PD vaccine. Reactivity after the second dose of each vaccine was similar to that with placebo. After the second dose of WVV, 67%–75% of children had hemagglutination-inhibition titers of ⩾40; after the SPV this figure was 88%–90%. The serologic response to the A/Victoria/75 antigen was better than the response to the A/New Jersey antigen after one dose of vaccine. Thus, two doses of PD vaccine resulted in the greatest hemagglutination-inhibiting antibody response and the least reactivity in the subjects aged three to 18 years.</abstract><note type="author-notes">Please address requests for reprints to Dr. Peter A. Gross, Johnson Hall, Room 118, Hackensack Hospital, Hackensack, NewJersey 07601.</note><relatedItem type="host"><titleInfo><title>Journal of Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>J Infect Dis.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0022-1899</identifier><identifier type="eISSN">1537-6613</identifier><identifier type="PublisherID">jid</identifier><identifier type="PublisherID-hwp">jinfdis</identifier><part><date>1977</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><detail type="issue"><caption>no.</caption><number>Supplement-3</number></detail><extent unit="pages"><start>S616</start><end>S625</end></extent></part></relatedItem><identifier type="istex">2F3479F240463BF422D7A2DA798B5E1D47BD5B16</identifier><identifier type="ark">ark:/67375/HXZ-WV6F7NPT-C</identifier><identifier type="DOI">10.1093/infdis/136.Supplement_3.S616</identifier><accessCondition type="use and reproduction" contentType="copyright">© 1977 the University of Chicago</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource><recordOrigin>Converted from (version 1.2.0) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-WV6F7NPT-C/record.json</uri></json:item></metadata><covers><json:item><extension>tiff</extension><original>true</original><mimetype>image/tiff</mimetype><uri>https://api.istex.fr/document/2F3479F240463BF422D7A2DA798B5E1D47BD5B16/covers/tiff</uri></json:item></covers><annexes><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-WV6F7NPT-C/annexes.pdf</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2F3479F240463BF422D7A2DA798B5E1D47BD5B16
|texte= Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary
}}
| This area was generated with Dilib version V0.6.33. |  |